Emergex closes US$11m Series A round led by Vickers Venture Partners
BIOTECH firm Emergex has raised more than US$11 million in a Series A funding round to develop synthetic vaccines for infectious diseases, it said on Thursday.
The investment round was led by Vickers Venture Partners.
Founded in 2016, Emergex focuses on developing vaccines to prevent diseases such as Zika, dengue fever, Ebola and the pandemic flu.
According to the company, its vaccines are unlike traditional vaccines which use live viruses. Instead, Emergex uses synthetic non-biological components that "programme immune cells to destroy pathogen-producing cells", it said.
In addition, chairman of Vickers Venture Partners Finian Tan will also join Emergex's board as a non-executive director.
Said Dr Tan: "We see great potential in Emergex's technology as it allows vaccines to be produced quickly, administered easily and sold at a fraction of current prices."
Singapore-based Vickers Venture Partners specialises in early-stage investments in Asia. Its portfolio covers the life sciences, technology, media and telecommunications, as well as consumer and financial services.
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Startups
High Court dismisses bid by co-founder and CTO to liquidate Cake Group
Semiconductor unicorn Silicon Box vows to avoid geopolitical mire
A cheat sheet of startup and tech M&As in South-east Asia
Zilingo ex-CEO’s criminal complaint is retaliation against whistleblowers: source
Gojek and ComfortDelGro Taxi to send untaken rides to each other’s platforms
SG fintech firm Bambu shuts down after missing profit targets, says founder